Podcast Episodes
Back to Search261: Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)
Episode 261
In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. D…
1 day, 3 hours ago
260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 2
Episode 260
Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 20…
6 days, 2 hours ago
259: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 1
Episode 259
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.
Michael Rome, who leads therapeu…
1 week, 1 day ago
258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 2
Episode 258
What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked meri…
1 week, 6 days ago
257: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 1
Episode 257
The gap between a “drug” and a true “product” is where many therapies fail.
Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Alb…
2 weeks, 1 day ago
256: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 2
Episode 256
The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where inf…
2 weeks, 6 days ago
255: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 1
Episode 255
When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to…
3 weeks, 1 day ago
254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 2
Episode 254
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?
In Part 1…
3 weeks, 6 days ago
253: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 1
Episode 253
What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?
Yuta Lee, Founder and CEO of Accelerated…
4 weeks, 1 day ago
252: How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds
Episode 252
Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?
In…
1 month ago